查看文章

Gravin, an A‐Kinase Anchoring Protein (AKAP) is a scaffolding protein in the heart involved in the modulation of cardiac contractility. Specifically, gravin scaffolds PKA, PKC, β‐arrestin and various other proteins to β₂‐adrenergic receptors (β₂‐ARs) and functions to modulate contractility by mediating β₂‐ARs desensitization. We previously found that disruption of gravin scaffolding, using gravin knockout (gravin‐t/t) mice, reduced cardiac hypertrophy induced by chronic β‐AR stimulation with isoproterenol (ISO; 60mg/kg/day for 14 days). However, for disruption of gravin scaffolding to be considered a therapeutic target, it will be important to show that inhibiting gravin scaffolding is a superior approach over conventional therapies. Hence, the goal of this study was to study the effects of carvedilol (CARV) in wild‐type (WT) versus gravin‐t/t animals; where CARV is the gold standard β‐blocker used to treat human heart …